| Literature DB >> 35107672 |
Phillip Cem Cezayirli1,2,3, Hatice Türe4, Uğur Türe5.
Abstract
Over the past 30 years, the treatment of deep and eloquent arteriovenous malformations (AVMs) has moved away from microneurosurgical resection and towards medical management and the so-called minimally invasive techniques, such as endovascular embolization and radiosurgery. The Spetzler-Martin grading system (and subsequent modifications) has done much to aid in risk stratification for surgical intervention; however, the system does not predict the risk of hemorrhage nor risk from other interventions. In more recent years, the ARUBA trial has suggested that unruptured AVMs should be medically managed. In our experience, although these eloquent regions of the brain should be discussed with patients in assessing the risks and benefits of intervention, we believe each AVM should be assessed based on the characteristics of the patient and the angio-architecture of the AVM, in particular venous hypertension, which may guide us to treat even high-grade AVMs when we believe we can (and need to) to benefit the patient. Advances in imaging and intraoperative adjuncts have helped us in decision making, preoperative planning, and ensuring good outcomes for our patients. Here, we present several cases to illustrate our primary points that treating low-grade AVMs can be more difficult than treating high-grade ones, mismanagement of deep and eloquent AVMs at the behest of dogma can harm patients, and the treatment of any AVM should be tailored to the individual patient and that patient's lesion.Entities:
Keywords: ARUBA trial; AVM; Arteriovenous malformation; Deep AVM; Deep venous drainage; Eloquent brain; Microneurosurgery; Spetzler–Martin
Mesh:
Year: 2022 PMID: 35107672 DOI: 10.1007/978-3-030-87649-4_2
Source DB: PubMed Journal: Adv Tech Stand Neurosurg ISSN: 0095-4829